ARDS (Aridis Pharmaceuticals) Interest Expense: $0.00 Mil (TTM As of Sep. 2023)


ARDS Aridis Pharmaceuticals Inc ARDS
12 GF Score
Price $0.00
View Full Analysis

What is Aridis Pharmaceuticals Interest Expense?

Aridis Pharmaceuticals ARDS -99.00% 12 Interest Expense is $0.00 Mil as of Sep. 2023. GuruFocus rates ARDS with a GF Score™ of 12/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Aridis Pharmaceuticals's interest expense for the three months ended in Sep. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Aridis Pharmaceuticals's Operating Income for the three months ended in Sep. 2023 was $ -0.87 Mil. Aridis Pharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was $ 0.00 Mil. GuruFocus does not calculate Aridis Pharmaceuticals's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Aridis Pharmaceuticals  (OTCPK:ARDS) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aridis Pharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-0.87 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was $0.85 Mil.

Aridis Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

GuruFocus does not calculate Aridis Pharmaceuticals's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Aridis Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Aridis Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aridis Pharmaceuticals Interest Expense Chart

Aridis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Interest Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 -0.25 -0.12

Aridis Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 0.00 0.00 0.00 0.00
ARDS
12GF Score
Aridis Pharmaceuticals Inc ARDS
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aridis Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $0.00 Mil mean?
Aridis Pharmaceuticals (ARDS) has a Interest Expense of $0.00 Mil as of Sep. 2023. Interest Expense is the amount a company pays on its long-term debt. View historical data on Aridis Pharmaceuticals and its competitors.
Is Aridis Pharmaceuticals' Interest Expense too high?
Aridis Pharmaceuticals' current Interest Expense is $0.00 Mil. Overall, Aridis Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aridis Pharmaceuticals' Interest Expense compare to ARTL and REVB?
Aridis Pharmaceuticals' Interest Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Aridis Pharmaceuticals and its competitors. Aridis Pharmaceuticals's current Interest Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aridis Pharmaceuticals stock overvalued right now?
Aridis Pharmaceuticals (ARDS) has a current Interest Expense of $0.00 Mil. The current Interest Expense is $0.00 Mil. Aridis Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Aridis Pharmaceuticals (ARDS), the current Interest Expense is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aridis Pharmaceuticals Business Description

Address 983 University Avenue, Building B, Los Gatos, CA, USA, 95032
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
12GF Score

Get the complete analysis for ARDS

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price